Abstract:AIM:To evaluate the efficacy of corneal stromal lenses combined with 0.1% cyclosporine A eye drops in patients with Mooren's ulcer and its effect on ocular surface inflammatory factors.METHODS:In this prospective randomized controlled trial, 200 patients(272 eyes)with Mooren's ulcer were enrolled from January 2022 to January 2024. Patients were randomly assigned to receive either corneal stromal lenses alone(control group: 100 patients, 136 eyes)or combined with 0.1% cyclosporine A eye drops(observation group: 100 patients, 136 eyes). All patients were followed up for 3 mo. Clinical efficacy, visual acuity improvement, recovery time, pain score, complications, and tear levels of interleukin(IL)-1β, IL-6, and tumor necrosis factor-α(TNF-α)were compared between the two groups.RESULTS:A total of 196 patients(268 eyes)completed follow-up, with 2 cases(2 eyes)lost to follow-up in each group and a lost to follow-up rate of 2.0%. The observation group showed a higher total effective rate(95.5% vs 83.6%, P<0.05). Postoperative best corrected visual acuity(LogMAR)of the observation group was significantly better than that of the control group(0.42±0.15 vs 0.65±0.18, P<0.001). Epithelial(5.24±1.15 vs 7.86±1.43 d)and stromal recovery(12.35±2.46 vs 16.72±3.15 d)were faster in the observation group(both P<0.001). Pain scores and complication rates of the observation group were lower than those of the control group(both P<0.001). Both groups showed reduced tear IL-1β, IL-6, and TNF-α levels postoperatively, with greater reductions in the observation group(P<0.001).CONCLUSION: Corneal stromal lenses combined with 0.1% cyclosporine A eye drops provide superior outcomes for Mooren's ulcer by enhancing visual recovery, accelerating corneal healing, reducing pain, and lowering complications, potentially through inhibition of ocular surface inflammatory factors.
